Impact Factor 2019: 1.940 (@Clarivate Analytics)
5-Year Impact Factor: 1.955 (@Clarivate Analytics)
  • Users Online: 1150
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 13  |  Issue : 7  |  Page : 295-300

Seroprotection after hepatitis B vaccination amongst infants aged between 12 and 24 months in Ho Chi Minh City, Vietnam


1 Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
2 Department of Pediatrics, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
3 Department of Microbiology and Parasitology, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
4 Center for training of Family Medicine University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam

Correspondence Address:
Giao Huynh
Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City
Vietnam
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.285828

Get Permissions

Objective: To assess levels of HBsAb amongst infants who received hepatitis B vaccine in the Expanded Program on Immunization in Vietnam. Methods: A cross-sectional study was carried out at 16 community health centers from February 2016 to July 2017. Eligible infants were tested for HBsAb and HBsAg. Structured questionnaires were used to collect relevant information about the demographics of the parents/caregivers and their infants after physical examination. Results: A total of 199 eligible infants were selected with a mean age of (17.3±4.5) months. Protective antibody levels with HBsAb ≥10 mIU/mL were detected in 68.3% of infants. Of these, antibody levels from 10 to 99 mIU/ mL were 48.5% of those tested and antibody levels ≥100 mlU/mL were recorded as 51.5%. No cases were recorded of being infected with hepatitis B virus. The rate of positive HBsAb level in those who were not wasting and 18 months old was less than that among those who were <18 months old (OR 0.49, 95% CI: 0.26-0.92, P<0.05) while the infants with wasting and <18 months were less likely to be positive HBsAb than those who were not wasting and of the same age group (OR 0.15, 95% CI: 0.04-0.55, P<0.05). Conclusions: Seroprotection against hepatitis B virus was low in the infants tested (at 68.3%), which suggests that the hepatitis B vaccine should be administered with one additional dose for infants between 12 and 24 months of age, particularly those with wasting.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed369    
    Printed17    
    Emailed0    
    PDF Downloaded191    
    Comments [Add]    

Recommend this journal